Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GLA-60 is a synthetic monosaccharide lipid A analogue, specifically 2-deoxy-4-O-phosphono-2-[(3R)-3-hydroxytetradecanamido]-3-O-[(3R)-3-tetradecanoyloxytetradecanoyl]-D-glucose. It functions as an immunomodulator, exhibiting many endotoxin-like activities but with low toxicity. GLA-60 has been investigated for its ability to stimulate various immune responses, including the production of cytokines like TNF-alpha, IL-1, IL-6, and nitric oxide, as well as activating natural killer cells and macrophages. Studies have explored its potential in protecting against viral and bacterial infections, inhibiting tumor metastasis and angiogenesis, and inducing tolerance to LPS lethality.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on GLA-60.